Your browser is no longer supported. Please, upgrade your browser.
Settings
BLUE bluebird bio, Inc. daily Stock Chart
BLUE [NASD]
bluebird bio, Inc.
Index- P/E- EPS (ttm)-7.01 Insider Own0.70% Shs Outstand46.38M Perf Week22.56%
Market Cap9.29B Forward P/E- EPS next Y-7.02 Insider Trans-55.31% Shs Float45.64M Perf Month8.07%
Income-289.80M PEG- EPS next Q-1.69 Inst Own- Short Float8.33% Perf Quarter40.44%
Sales32.80M P/S283.09 EPS this Y-46.90% Inst Trans0.00% Short Ratio3.99 Perf Half Y100.50%
Book/sh25.00 P/B8.01 EPS next Y-4.00% ROA-22.90% Target Price199.59 Perf Year206.35%
Cash/sh15.71 P/C12.74 EPS next 5Y- ROE-28.80% 52W Range64.15 - 222.03 Perf YTD12.41%
Dividend- P/FCF- EPS past 5Y47.20% ROI-27.00% 52W High-9.83% Beta2.06
Dividend %- Quick Ratio9.90 Sales past 5Y47.50% Gross Margin- 52W Low212.08% ATR8.97
Employees418 Current Ratio9.90 Sales Q/Q381.30% Oper. Margin- RSI (14)66.53 Volatility7.31% 4.52%
OptionableYes Debt/Eq0.14 EPS Q/Q16.60% Profit Margin- Rel Volume1.66 Prev Close194.65
ShortableYes LT Debt/Eq0.14 EarningsJan 31 AMC Payout- Avg Volume953.54K Price200.20
Recom2.10 SMA2013.02% SMA5016.16% SMA20061.87% Volume1,583,675 Change2.85%
Dec-21-17Initiated Oppenheimer Perform
Dec-13-17Reiterated Barclays Overweight $162 → $209
Dec-13-17Downgrade Maxim Group Buy → Hold $200
Dec-11-17Upgrade Jefferies Hold → Buy $130 → $211
Dec-11-17Reiterated Goldman Buy $186 → $309
Dec-11-17Reiterated Cantor Fitzgerald Underweight $58 → $113
Dec-05-17Initiated Canaccord Genuity Buy $202
Nov-30-17Reiterated Maxim Group Buy $170 → $200
Nov-06-17Downgrade Evercore ISI Outperform → In-line
Nov-03-17Upgrade Morgan Stanley Underweight → Equal-Weight
Nov-02-17Upgrade BTIG Research Neutral → Buy $177
Oct-16-17Upgrade Evercore ISI In-line → Outperform
Oct-11-17Resumed Jefferies Hold $126
Oct-09-17Reiterated Maxim Group Buy $100 → $170
Oct-06-17Resumed Goldman Buy $186
Oct-02-17Downgrade Morgan Stanley Equal-Weight → Underweight
Sep-05-17Reiterated Wells Fargo Outperform $134 → $158
Aug-17-17Initiated Evercore ISI In-line $102
Aug-07-17Reiterated Morgan Stanley Equal-Weight $103 → $105
Jun-30-17Downgrade BTIG Research Buy → Neutral
Jan-23-18 09:39AM  Bluebird Up on Buyout Speculation After Celgene/Juno Deal Zacks
08:00AM  Celgene's Investments Are Soaring Motley Fool
07:31AM  These 3 Stocks Have Doubled Investors' Money Motley Fool
Jan-22-18 02:05PM  Why bluebird bio Is Soaring 11.9% Today Motley Fool +10.63%
02:00PM  Bluebird Bio Shouldn't Be Blue Bloomberg
11:23AM  Biotech M&A takes off as Sanofi and Celgene spend $20 billion Reuters
Jan-17-18 07:30AM  Could Little Known Orgenesis (ORGS) Become A Dominant Player in The Multi Billion Dollar Cell Therapy Market? ACCESSWIRE +7.28%
Jan-14-18 09:00AM  5 Biotech Stocks That Could Be Bought Out in 2018 Motley Fool
Jan-11-18 07:31PM  What bluebird bio Wants You to Know About Its Business Motley Fool
08:00AM  Up 188.7%, Is bluebird bio. Stock Still a Strong Buy? Motley Fool
Jan-08-18 04:05PM  bluebird bio Announces Closing of Over-Allotment Option in Public Offering Business Wire
Jan-02-18 04:22PM  Here's How bluebird bio, Inc. Crushed It in 2017 Motley Fool
Dec-28-17 11:46AM  2018 Should Be Better for Celgene Corporation and CELG Stock InvestorPlace
Dec-21-17 04:15PM  bluebird bio to Present at Investor Conferences in January Business Wire
Dec-20-17 06:32AM  What to Expect From Celgene Corporation in 2018 Motley Fool
Dec-19-17 11:02AM  Celgene Stock Up Huge On Exciting CAR-T News Motley Fool
11:02AM  Celgene Shareholders Excited by CAR-T News Motley Fool
Dec-15-17 06:15PM  Bluebird Bio Inc (BLUE) President and CEO Nick Leschly Sold $21.6 million of Shares GuruFocus.com
Dec-13-17 04:09PM  This Biotech Stock Seen As Cheapest Among Rivals In Cancer Drugs Investor's Business Daily
12:31PM  ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More Benzinga
11:30AM  Bluebird Bio Stumbles Over Secondary Offering 24/7 Wall St.
10:24AM  Analyst Doubts Bluebird Bio Shares Up 200% In 2017 Can Fly Much Higher Benzinga
08:00AM  Here's Why Everyone's So Excited About bluebird bio Motley Fool
07:31AM  5 Biotech Buyout Candidates for 2018 Motley Fool
Dec-12-17 08:46PM  bluebird bio Announces Pricing of Public Offering of Common Stock Business Wire -5.38%
02:28PM  10 Biggest Stock Market Successes of 2017 InvestorPlace
12:52PM  ETFs with exposure to bluebird bio, Inc. : December 12, 2017 Capital Cube
Dec-11-17 05:08PM  What Happened in the Stock Market Today Motley Fool +17.91%
05:00PM  4 Stocks Move to Start the Week GuruFocus.com
04:26PM  Apple and Chesapeake Energy rise; Spark Therapeutics sinks Associated Press
04:19PM  Bluebird Bio stock retreats from records after announcing stock offering MarketWatch
04:01PM  bluebird bio Announces Proposed Public Offering of Common Stock Business Wire
03:30PM  Bluebird Bio rallies, Spark Therapeutics craters after unveiling data at ASH meeting MarketWatch
02:25PM  Life-Shortening Blood Disease Gets Rush of Research Bloomberg
01:45PM  Spark Therapeutics' gene therapy program brings stock dow... CNBC Videos
01:43PM  Bluebird could be on the way to a cure for sickle cell disease CNBC
12:42PM  Goldman: Bluebird Bio Is One Step Closer To A Sickle Cell Cure Benzinga
12:23PM  Bluebird Bio Becoming Household Name With This Promising Cancer Treatment TheStreet.com
12:06PM  Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today Zacks
11:47AM  Bluebird Bio gives hope to cancer patients CNBC Videos
11:27AM  Biotech winners and losers: ASH Hematology Conference CNBC Videos
10:53AM  Jefferies Calls Bluebird Bio The 'Star' Of This Year's ASH Meeting Benzinga
10:34AM  Stocks Trade Higher Following Explosion at New York's Port Authority TheStreet.com
10:21AM  Despite Bluebird Bio's 17% Rally, Another 55% Surge Could Be Coming TheStreet.com
09:40AM  Blueprint Medicines and Bluebird Bio Soar on ASH Announcements -- Biotech Movers TheStreet.com
09:19AM  After Data Release, Cantor Fitzgerald Doubles Bluebird Bio Price Target Benzinga
09:15AM  bluebird bio Stock Soars on Unprecedented Blood Cancer Study Results Motley Fool
09:05AM  Highlights from ASH Sent bluebird Bio Inc (BLUE) Shares Skyrocketing; J.P. Morgan Cheers SmarterAnalyst
09:05AM  Morning Movers: Bluebird Bio, Solar Stocks Soar; Paccar Falls Barrons.com
09:00AM  bluebird bio Presents Updated Data from HGB-205 Study of LentiGlobinTM Gene Therapy in Patients with Severe Sickle Cell Disease and Transfusion-Dependent -Thalassemia at American Society of Hematology Annual Meeting Business Wire
08:32AM  Bluebird Bio shares soar 24% premarket as Goldman raises price target to $309 from $186 MarketWatch
Dec-10-17 04:30PM  bluebird bio Presents New Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent -Thalassemia at American Society of Hematology Annual Meeting Business Wire
04:30PM  bluebird bio Announces Updated Clinical Results from Ongoing Phase 1 Multicenter Study of LentiGlobin Gene Therapy in Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting Business Wire
10:30AM  Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting Business Wire
10:30AM  Bluebird, Celgene Myeloma Therapy Appears to Improve in Time Bloomberg
Dec-07-17 08:00AM  bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy Business Wire +5.33%
07:31AM  Here's Why bluebird bio's Shares Soared 24% in November Motley Fool
Dec-05-17 09:58AM  Bluebird Bio (BLUE) Bullish Camp Just Got Stronger SmarterAnalyst
Nov-30-17 07:30AM  Are Viruses a Problem for CAR-T Drugmakers? Motley Fool
Nov-29-17 08:03AM  A Virus Shortage? BlueBird Bio Buys A Factory To Make Its Own Forbes
08:00AM  bluebird bio Acquires Manufacturing Facility in North Carolina and Executes Multiple Global Supply Agreements to Enhance Ability to Deliver Gene Therapies to Patients Business Wire
Nov-27-17 12:22PM  ETFs with exposure to bluebird bio, Inc. : November 27, 2017 Capital Cube
Nov-22-17 08:30AM  New Research Coverage Highlights bluebird bio, Accuray, Carlisle Companies, Genesco, Portland General Electric, and Ring Energy Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-20-17 10:12AM  The Forbes Healthcare Summit: The Final Agenda Forbes
Nov-16-17 11:16AM  ETFs with exposure to bluebird bio, Inc. : November 16, 2017 Capital Cube
08:30AM  Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma Business Wire
08:00AM  bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin in Patients with Transfusion-Dependent -Thalassemia (TDT) and 0/0 Genotype Business Wire
Nov-13-17 10:16AM  A Rare Quarterly Appearance by bluebird bio Inc.'s Management Motley Fool
09:31AM  3 Top Healthcare Stocks to Buy in November Motley Fool
Nov-10-17 01:30PM  The Forbes Healthcare Summit 2017: The Draft Agenda Forbes
Nov-06-17 11:11AM  ETFs with exposure to bluebird bio, Inc. : November 6, 2017 Capital Cube -7.36%
08:18AM  3 Stocks to Buy for a Better Tomorrow Motley Fool
Nov-03-17 10:08AM  bluebird bio, Inc. :BLUE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 Capital Cube
08:34AM  3 Reasons It's Smart to Buy Celgene's Stock Now Motley Fool
12:38AM  Edited Transcript of BLUE earnings conference call or presentation 1-Nov-17 12:30pm GMT Thomson Reuters StreetEvents
Nov-02-17 05:18PM  Here's Why bluebird bio Inc. Is Surging Again Today Motley Fool +7.76%
08:10AM  Today's Research Reports on Stocks to Watch: Momenta Pharmaceuticals and bluebird bio ACCESSWIRE
Nov-01-17 05:08PM  What Happened in the Stock Market Today Motley Fool
04:02PM  How Blood-Disease Data Sent These 2 Biotech Stocks Flying Investor's Business Daily
02:10PM  Why bluebird bio Inc. Jumped Higher Today Motley Fool
07:39AM  Bluebird reports 3Q loss Associated Press
07:30AM  bluebird bio to Present New Data from Clinical Studies of LentiGlobinTM Gene Therapy in Transfusion-Dependent -Thalassemia and Severe Sickle Cell Disease and bb2121 in Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting Business Wire
07:30AM  bluebird bio Reports Third Quarter 2017 Financial Results and Recent Operational Progress Business Wire
Oct-31-17 04:05PM  bluebird bio Announces ASH Abstract Conference Call on November 1st and Upcoming Investor Events in November Business Wire
Oct-20-17 07:31AM  Celgene Could Be the Best CAR-T Stock to Buy, Not Gilead Sciences Motley Fool
Oct-12-17 08:10AM  Today's Research Reports on Stocks to Watch: MannKind Corporation and Bluebird Bio ACCESSWIRE
Oct-06-17 04:16PM  bluebird bio to Present at Chardan Gene Therapy Conference Business Wire
Oct-04-17 03:00PM  bluebird bio Announces Publication of Interim Data from Starbeam Study of Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine Business Wire
Oct-03-17 10:42AM  Why bluebird bio, Inc. Stock Gained 10% in September Motley Fool
Oct-02-17 04:10PM  Why Bluebird's Downgrade Sent These Two Rivals Skyrocketing Investor's Business Daily -8.66%
03:56PM  Bluebird Bio: So Much for That Gilead Boost Barrons.com
12:00PM  Here's Why Bluebird Bio (BLUE) Stock Is Falling Today Zacks
07:40AM  Featured Company News - Bluebird Bio Declares Treatment of 1st Patient with 2nd Anti-BCMA CAR T bb21217 in CRB-402 Phase-1 Study ACCESSWIRE
Sep-29-17 10:54AM  Why Biotech and Tech Will Push Stocks Higher In 4Q Investopedia
08:37AM  Should You Be Concerned About bluebird bio Incs (BLUE) Risks? Simply Wall St.
Sep-28-17 04:57PM  Bluebird Hits High On Bullish Report Highlighting Blood Drugs Investor's Business Daily +9.76%
04:30PM  Why BlackBerry, AbbVie, and bluebird bio Jumped Today Motley Fool
04:05PM  bluebird bio Announces First Patient Treated with Second Anti-BCMA CAR T bb21217 in CRB-402 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma Business Wire
02:38PM  Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio Motley Fool
Sep-26-17 09:32AM  3 Biotech Stocks With Major Catalysts in October Motley Fool
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. The company's lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Davidson DavidChief Medical OfficerJan 08Option Exercise5.501,2006,60014,855Jan 09 04:05 PM
Davidson DavidChief Medical OfficerJan 08Sale174.071,200208,88313,655Jan 09 04:05 PM
Gregory Philip DChief Scientific OfficerJan 05Sale173.381,712296,82023,772Jan 09 04:06 PM
Leschly NickPresident and CEOJan 05Sale173.385,435942,298170,297Jan 09 04:06 PM
Davidson DavidChief Medical OfficerJan 05Sale173.382,322402,57913,655Jan 09 04:05 PM
Walsh Jeffrey T.Chief FinancialJan 05Sale173.383,060530,53024,245Jan 09 04:07 PM
Cole JasonChief Legal OfficerJan 05Sale173.381,129195,74119,798Jan 09 04:05 PM
Davidson DavidChief Medical OfficerJan 03Option Exercise5.506,00033,00221,977Jan 05 04:10 PM
Gregory Philip DChief Scientific OfficerJan 03Option Exercise50.511,25063,13827,734Jan 05 04:11 PM
Gregory Philip DChief Scientific OfficerJan 03Sale180.692,250406,55025,484Jan 05 04:11 PM
Davidson DavidChief Medical OfficerJan 03Sale180.306,0001,081,78115,977Jan 05 04:10 PM
Leschly NickPresident and CEODec 13Option Exercise5.5037,873208,317293,232Dec 15 04:09 PM
Leschly NickPresident and CEODec 13Sale184.08117,50021,629,119175,732Dec 15 04:09 PM
Vachon MarkDirectorDec 11Option Exercise30.476,000182,8208,000Dec 13 04:10 PM
Walsh Jeffrey T.Chief FinancialDec 11Option Exercise24.479,900242,25337,205Dec 13 04:09 PM
Vachon MarkDirectorDec 11Sale216.647,0001,516,4651,000Dec 13 04:10 PM
Walsh Jeffrey T.Chief FinancialDec 11Sale216.549,9002,143,78527,305Dec 13 04:09 PM
Gregory Philip DChief Scientific OfficerDec 01Option Exercise50.511,25063,13828,734Dec 05 04:08 PM
Davidson DavidChief Medical OfficerDec 01Option Exercise5.504,00022,00219,977Dec 05 04:08 PM
HIGH SUSANNA GATTIChief Operating OfficerDec 01Sale172.151,282220,69613,718Dec 05 04:09 PM
Davidson DavidChief Medical OfficerDec 01Sale172.424,000689,67915,977Dec 05 04:08 PM
Gregory Philip DChief Scientific OfficerDec 01Sale172.542,250388,21126,484Dec 05 04:08 PM
Walsh Jeffrey T.Chief FinancialNov 10Option Exercise19.999,900197,87037,205Nov 14 04:02 PM
Walsh Jeffrey T.Chief FinancialNov 10Sale149.589,9001,480,86527,305Nov 14 04:02 PM
Gregory Philip DChief Scientific OfficerNov 01Option Exercise50.511,25063,13829,734Nov 03 04:07 PM
Walsh Jeffrey T.Chief FinancialNov 01Option Exercise5.5035,000192,51462,305Nov 03 04:08 PM
Leschly NickPresident and CEONov 01Option Exercise5.502,12711,699257,486Nov 03 04:08 PM
Davidson DavidChief Medical OfficerNov 01Option Exercise5.504,00022,00219,977Nov 03 04:06 PM
Walsh Jeffrey T.Chief FinancialNov 01Sale151.3835,0005,298,32627,305Nov 03 04:08 PM
Leschly NickPresident and CEONov 01Sale145.172,127308,779255,359Nov 03 04:08 PM
Gregory Philip DChief Scientific OfficerNov 01Sale144.312,250324,69027,484Nov 03 04:07 PM
Davidson DavidChief Medical OfficerNov 01Sale145.214,000580,82215,977Nov 03 04:06 PM
Leschly NickPresident and CEOOct 23Sale145.263,700537,455255,359Oct 24 04:17 PM
Leschly NickPresident and CEOOct 20Sale145.023,350485,813259,059Oct 24 04:17 PM
Leschly NickPresident and CEOOct 17Sale145.0510,8231,569,840262,409Oct 19 04:13 PM
Walsh Jeffrey T.Chief FinancialOct 10Option Exercise5.504,90026,95232,205Oct 11 04:37 PM
Walsh Jeffrey T.Chief FinancialOct 10Sale129.944,900636,72427,305Oct 11 04:37 PM
Gregory Philip DChief Scientific OfficerOct 02Option Exercise50.511,25063,13830,734Oct 04 04:02 PM
Davidson DavidChief Medical OfficerOct 02Option Exercise5.504,00022,00219,977Oct 04 04:02 PM
Gregory Philip DChief Scientific OfficerOct 02Sale131.822,250296,60228,484Oct 04 04:02 PM
Davidson DavidChief Medical OfficerOct 02Sale131.314,000525,24915,977Oct 04 04:02 PM
MARAGANORE JOHNDirectorSep 14Option Exercise2.0918,86839,43424,711Sep 18 04:09 PM
MARAGANORE JOHNDirectorSep 14Sale131.2118,8682,475,7335,843Sep 18 04:09 PM
Vachon MarkDirectorSep 12Option Exercise30.476,000182,8208,000Sep 14 04:09 PM
Vachon MarkDirectorSep 12Sale126.826,000760,9232,000Sep 14 04:09 PM
Walsh Jeffrey T.Chief FinancialSep 11Option Exercise5.504,90026,95232,205Sep 13 04:07 PM
Walsh Jeffrey T.Chief FinancialSep 11Sale125.734,900616,06527,305Sep 13 04:07 PM
Leschly NickPresident and CEOSep 01Option Exercise5.506,36435,005295,732Sep 05 04:01 PM
Davidson DavidChief Medical OfficerSep 01Option Exercise5.5012,00066,00527,977Sep 06 04:06 PM
Gregory Philip DChief Scientific OfficerSep 01Option Exercise50.511,25063,13831,734Sep 06 04:06 PM
Davidson DavidChief Medical OfficerSep 01Sale129.0812,0001,548,90415,977Sep 06 04:06 PM
Gregory Philip DChief Scientific OfficerSep 01Sale126.062,250283,63529,484Sep 06 04:06 PM
Leschly NickPresident and CEOSep 01Sale130.0422,5002,925,983273,232Sep 05 04:01 PM
Schenkein David PDirectorAug 31Option Exercise8.162,00016,3125,176Sep 05 04:02 PM
LYNCH DANIELDirectorAug 31Option Exercise5.505002,7503,300Sep 05 04:01 PM
Walsh Jeffrey T.Chief FinancialAug 31Option Exercise5.5012,00066,00539,305Sep 05 04:02 PM
LYNCH DANIELDirectorAug 31Sale120.0050060,0002,800Sep 05 04:01 PM
Schenkein David PDirectorAug 31Sale115.072,000230,1453,176Sep 05 04:02 PM
Walsh Jeffrey T.Chief FinancialAug 31Sale125.0112,0001,500,09127,305Sep 05 04:02 PM
Leschly NickPresident and CEOAug 31Sale115.0924,3332,800,461289,368Sep 05 04:01 PM
Leschly NickPresident and CEOAug 30Sale115.1825,6672,956,307313,701Aug 31 04:16 PM
Walsh Jeffrey T.Chief FinancialAug 28Option Exercise5.501,2506,87628,555Aug 30 04:17 PM
Walsh Jeffrey T.Chief FinancialAug 28Sale107.061,250133,82627,305Aug 30 04:17 PM
MARAGANORE JOHNDirectorAug 24Option Exercise2.0913,83928,92419,682Aug 28 04:17 PM
MARAGANORE JOHNDirectorAug 24Sale95.8111,0851,062,1088,597Aug 28 04:17 PM
Mandell JamesDirectorAug 14Sale95.951,00095,9501,000Aug 15 04:05 PM
Walsh Jeffrey T.Chief FinancialAug 10Option Exercise5.501,2506,87628,555Aug 14 04:03 PM
Walsh Jeffrey T.Chief FinancialAug 10Sale95.411,250119,26527,305Aug 14 04:03 PM
Gregory Philip DChief Scientific OfficerAug 07Option Exercise50.5150025,25531,234Aug 09 04:01 PM
Gregory Philip DChief Scientific OfficerAug 07Sale99.0075074,25030,484Aug 09 04:01 PM
Sullivan EricPrincipal Accounting OfficerAug 04Option Exercise53.6844523,8906,119Aug 07 04:02 PM
Sullivan EricPrincipal Accounting OfficerAug 04Sale95.2144542,3705,674Aug 07 04:02 PM
Sullivan EricPrincipal Accounting OfficerAug 03Option Exercise22.204169,2376,090Aug 07 04:02 PM
Sullivan EricPrincipal Accounting OfficerAug 03Sale92.3541638,4185,674Aug 07 04:02 PM
MARAGANORE JOHNDirectorAug 02Sale96.742,754266,4255,843Aug 28 04:17 PM
Gregory Philip DChief Scientific OfficerAug 01Option Exercise50.5175037,88332,234Aug 03 04:04 PM
Davidson DavidChief Medical OfficerAug 01Option Exercise2.093,0006,27018,977Aug 03 04:04 PM
Gregory Philip DChief Scientific OfficerAug 01Sale93.081,500139,62030,734Aug 03 04:04 PM
Davidson DavidChief Medical OfficerAug 01Sale92.373,000277,09915,977Aug 03 04:04 PM
Walsh Jeffrey T.Chief FinancialJul 10Option Exercise5.502,50013,75129,805Jul 12 04:15 PM
Walsh Jeffrey T.Chief FinancialJul 10Sale99.892,500249,72427,305Jul 12 04:15 PM
Davidson DavidChief Medical OfficerJul 07Sale100.491,200120,58315,977Jul 11 04:07 PM
Gregory Philip DChief Scientific OfficerJul 06Option Exercise50.511,25063,13833,734Jul 10 04:03 PM
Cole JasonChief Legal OfficerJul 06Option Exercise22.535,126115,48920,927Jul 07 04:04 PM
Gregory Philip DChief Scientific OfficerJul 06Sale103.832,250233,61631,484Jul 10 04:03 PM
Sullivan EricPrincipal Accounting OfficerJul 05Option Exercise51.753,580185,2529,987Jul 07 04:03 PM
Davidson DavidChief Medical OfficerJul 05Option Exercise2.095,00010,45022,177Jul 07 04:03 PM
Sullivan EricPrincipal Accounting OfficerJul 05Sale107.284,313462,7065,674Jul 07 04:03 PM
Davidson DavidChief Medical OfficerJul 05Sale105.285,000526,39517,177Jul 07 04:03 PM
Sullivan EricPrincipal Accounting OfficerJun 29Option Exercise36.626,728246,41113,194Jun 30 04:01 PM
Sullivan EricPrincipal Accounting OfficerJun 29Sale108.966,787739,5306,407Jun 30 04:01 PM
Leschly NickPresident and CEOJun 27Sale108.0525,0002,701,164349,368Jun 29 04:01 PM
LYNCH DANIELDirectorJun 23Option Exercise3.794,00015,1466,800Jun 27 04:05 PM
LYNCH DANIELDirectorJun 23Sale109.094,000436,3622,800Jun 27 04:05 PM
LYNCH DANIELDirectorJun 20Option Exercise2.092,5005,2165,300Jun 22 04:04 PM
LYNCH DANIELDirectorJun 20Sale120.032,500300,0702,800Jun 22 04:04 PM
Gregory Philip DChief Scientific OfficerJun 16Sale109.283,295360,08532,484Jun 22 04:03 PM
Walsh Jeffrey T.Chief FinancialJun 12Option Exercise2.092,5005,21629,805Jun 14 04:18 PM
Walsh Jeffrey T.Chief FinancialJun 12Sale109.532,500273,83127,305Jun 14 04:18 PM
LYNCH DANIELDirectorJun 08Option Exercise2.092,5005,2165,300Jun 12 04:57 PM